根据肾脏疾病预后质量倡议(K/DOQI)指南,为了降低β2-微球蛋白淀粉样变性的风险,noncuprophane(证据),应使用高通量透析器(opinion)。目前没有可用的治疗方法,除了肾移植,可以阻止β2-微球蛋白淀粉样变性的疾病进展或提供症状缓解(证据)。筛选β2-微球蛋白淀粉样变性,包括测量血清β2-微球蛋白水平,不推荐(opinion)。
According to the Kidney disease outcomes quality initiative (K/DOQI)
guideline, in order to decrease risk of beta2-microglobulin amyloidosis, noncuprophane (EVIDENCE), high-flux dialyzers (OPINION) should be used. No currently available therapy, except kidney transplantation, can stop disease progression of beta2-microglobulin amyloidosis or provide symptomatic relief (EVIDENCE). Screening for beta2-microglobulin amyloidosis, including measurement of serum levels of beta2-microglobulin, is not recommended (OPINION).